In this article you will learn:
- What makes phase II different from phase I and phase III trials?
- How many patients typically take part in a phase II trial, and for how long?
- What is "proof of concept" and why does it matter for your treatment?
- How do researchers decide on the dose you will receive?
- What do terms like placebo-controlled, randomised and double-blind mean for you as a participant?
- What happens to the results, and how often does a treatment move on to phase III?
- What should you ask your investigator before agreeing to join a phase II trial?
What is a phase 2 clinical trial?
A phase II clinical trial is a study conducted in patients who have the disease or condition a medicine is intended to treat. It is designed to explore whether the treatment works. It continues checking the medicine's safety in the population it is meant to help[1]. It follows phase I, in which the medicine is usually tested in healthy volunteers or a small number of patients mainly to check safety and dosing[2].
Phase II trials try to answer several specific questions at once. They ask whether the medicine is safe in patients. They ask what it does to the body (its pharmacodynamics). They ask whether it seems to work at all, at what dose, and how a later confirmatory trial should be designed[3]. When a medicine fails during development, it is often at this stage that researchers discover it does not work as expected. It is also at this stage that they may discover it causes unforeseen toxic effects[1].
Who takes part in a phase 2 trial, and how long does it last?
Phase II trials are usually carried out in around 100 to 500 patients, often with more than 30 participants per treatment group[3]. The U.S. Food and Drug Administration describes phase 2 studies as typically involving up to several hundred patients with the disease or condition being studied[2].
Participants are selected using strict inclusion criteria. This keeps the study group relatively homogenous. It also makes the results easier to interpret once the trial ends[3]. In cancer trials specifically, phase II studies are generally designed to recruit patients with a tumour type of particular relevance to the drug being investigated[4].
In terms of duration, phase II trials are typically short, lasting several weeks to a few months[3]. The FDA gives a somewhat wider range, stating that phase 2 studies can last from several months up to two years[2].
| Aspect | Typical description |
|---|---|
| Number of participants | Around 100–500 patients with the disease or condition, often 30+ per treatment group[3] |
| Length of study | Several weeks to several months[3]; FDA states several months up to 2 years[2] |
| Main purpose | Explore efficacy and further assess safety[2] |
| Selection of participants | Strict inclusion criteria, relatively homogenous population[3] |
What does "proof of concept" mean for your treatment?
Proof of concept is the demonstration that a treatment shows some sign of activity or response in the patient population it is meant to help. It is not full confirmation of efficacy — that step is reserved for phase III[3]. Phase II studies often use surrogate endpoints rather than clinical endpoints to obtain this early signal[1].
Proof of concept must clearly show clinical improvement so that the existence of a response can be established[3]. The outcomes of this analysis are considered when deciding whether the medicine's development continues into phase III. This decision is often described as "go/no-go"[1].
For radiation oncology and cancer trials specifically, phase II trials are designed to determine whether a new treatment shows sufficiently promising efficacy to justify a large-scale, randomised phase III trial. At the same time, they continue to assess safety in more detail[5].
How is your dose chosen during a phase 2 trial?
One of the central tasks of phase II is finding the dose and treatment schedule to be carried forward into phase III. Dose-response studies aim to discover the minimum effective dose — the smallest dose at which an effect is observed — and the optimal dose, at which the desired effect is seen without unacceptable risk[3].
Proof of concept is usually tested at the maximum tolerated dose (MTD). This approach reduces the chance of a false-negative result. It also gives the clearest possible signal of the drug's pharmacodynamic effect. Typically, dose-response studies use randomised parallel-group designs comparing three or more dosage levels, one of which may be a placebo (a dose of zero). This design lets researchers plot how the effect changes as the dose rises, rather than simply confirming that a single fixed dose produces some benefit[3].
In cancer research, phase I trials establish dose-limiting toxicities and the maximum tolerated dose beforehand. This information is then used to identify a recommended phase II dose (RP2D) carried into the next stage[4].
What do placebo, randomisation and blinding mean for you as a participant?
In phase II and phase III trials, there are usually two treatment groups. One receives the active medicine, and the other receives either the current best available treatment or a placebo — a dummy medicine with no effect on the body. These studies are usually run as double-blind, randomised studies[6].
- Randomised means the treatment groups are assigned by chance, usually using a computer-generated random code that cannot be influenced by the doctor or anyone else[6].
- Double-blind means neither you nor your doctor knows whether you are receiving the active medicine or the comparator/placebo[6].
- Placebo-controlled means some participants receive a placebo under exactly the same conditions as the active medicine. This allows researchers to separate effects caused by the medicine from effects that would have occurred anyway[6].
If there is an existing standard treatment for the condition being studied, that standard treatment is typically used as the comparator instead of a placebo. A placebo is used only when there is no current treatment available[4]. Every detail of how the trial is run is set out in advance in a document called the study protocol. The data collected from you during the trial is recorded in a Case Record Form (CRF). Understanding these terms before you enrol matters, because they explain why you may not be told which treatment you are receiving until the trial, or your part in it, has ended[6].
What exactly is being measured while you take part?
Phase II trials are built to answer a defined set of questions. They explore whether the medicine is safe in patients, what it does to the body, whether it appears to work and at what dose, and how future confirmatory trials should be designed[3].
- Exploratory analysis of multiple possible endpoints — the specific measures used to judge whether the treatment is working[1];
- Exploratory analysis of therapeutic regimens, including any other medications taken at the same time (concomitant medications)[1];
- Exploratory analysis of which patient groups respond best (for example, mild versus severe disease), to help define who should be studied in phase III[1].
In cancer trials, phase II also further explores the optimal dose, dosing frequency and route of administration alongside a preliminary evaluation of efficacy. This combined assessment helps decide whether the treatment is worth testing in a larger phase III trial[4]. Taken together, these exploratory analyses mean that a single phase II trial is really answering several interconnected questions at once, rather than testing one simple hypothesis about whether the drug works[1].
How does phase II differ from phase I, III and IV?
Phase I studies are often the first time a drug is given to humans. They are designed primarily to establish safety and appropriate dosage, typically in 20 to 100 healthy volunteers or patients over several months. Phase II shifts the focus to whether the treatment is effective in the target patient population, while continuing to gather safety data[2].
| Phase | Typical participants | Typical duration | Main purpose |
|---|---|---|---|
| Phase 1 | 20–100 healthy volunteers or patients[2] | Several months[2] | Safety and dosage[2] |
| Phase 2 | Up to several hundred patients with the disease/condition[2] | Several months to 2 years[2] | Efficacy and side effects[2] |
| Phase 3 | 300–3,000 volunteers with the disease/condition[2] | 1 to 4 years[2] | Efficacy and monitoring of adverse reactions[2] |
According to the FDA, approximately 70% of drugs that enter phase 1 move on to phase 2, and approximately 33% of drugs in phase 2 move on to phase 3. Phase 3 trials are sometimes called pivotal studies because their results are typically used to support regulatory approval[2]. After a medicine is approved, phase 4 studies continue to look for less common side effects. They also evaluate the treatment's effectiveness in patient groups that may differ from those in the original studies[4].
Why can't a phase 2 trial prove a treatment works on its own?
Phase II studies are too small on their own to provide sufficient evidence about efficacy and safety. Building as much information as possible about how the medicine behaves in patients at this stage reduces the risk of failure at the next, more complex and costly stage of development[6].
There are documented cases in the scientific literature where promising efficacy or safety results seen in phase II trials were not confirmed in the subsequent phase III trial. This is one reason why a positive phase II result is described as encouraging rather than conclusive. It is also why a separate, larger confirmatory trial is required before a treatment can be considered proven[5].
What regulatory rules protect you during a phase 2 trial?
Phase 1, 2 and 3 clinical trials are conducted before a medicinal product is authorised for the market, and all trial procedures are strictly regulated to protect the rights and safety of participants. Quality assurance measures for the conduct of clinical trials follow Good Clinical Practice (GCP), a set of standards designed to ensure the results are reliable and that ethical and legal conditions are respected[7].
A trial must comply with all relevant ethical principles, including Good Clinical Practice and the Declaration of Helsinki. In Europe, trial data is collected in public databases, including the EudraCT database (for past trials) and the Clinical Trials Information System (CTIS), where you or your family can look up ongoing and completed studies. This public transparency means that, in principle, anyone can trace how a particular phase II trial was registered, conducted and reported, long before its results are summarised in a scientific paper[7].
What does taking part in a phase 2 trial involve for you in practice?
Because phase II studies are carried out in patients rather than healthy volunteers, they are usually run at several hospital sites by hospital doctors, referred to as investigators. This is different from the specialised units typically used for phase I[6].
- You will be asked to give signed informed consent before joining, confirming that you understand and accept the requirements set out in the informed consent form and trial protocol[8];
- You will typically need to meet specific inclusion criteria related to your diagnosis, prior treatments and general health before you can be enrolled[8];
- Blood samples and other test results collected from you may be sent to a single central laboratory shared by all participating hospital sites, so that results can be compared consistently[6].
The Cleveland Clinic's phase 2 basket study of the oral, reversible tyrosine kinase inhibitor BAY 2927088 in patients with metastatic or unresectable solid tumours carrying HER2-activating mutations illustrates one example of this in practice, with an open-label design and defined eligibility criteria for each participating cohort. A basket study of this kind groups patients by the genetic mutation driving their tumour rather than by the organ in which the cancer originated[8].
When should you talk to your doctor or investigator before or during a phase 2 trial?
Before agreeing to take part, ask your investigator to explain, in plain language, what the study protocol requires of you, what the possible benefits and risks are, and whether you will know which treatment (active medicine, comparator, or placebo) you are receiving[6]. Ask specifically what dose you will receive and how it was determined, since dose-finding is one of the central goals of phase II[3].
Contact your investigator or study team promptly if you notice any new or worsening symptom while you are enrolled. Phase II is precisely the stage at which safety information is still being actively gathered, and unforeseen side effects may first come to light during this period. Remember that a positive result in a phase II trial is not the same as proof that a treatment works. Ask what a "go/no-go" decision would mean for you and whether you might be invited to join a subsequent phase III trial[1]. It is also reasonable to ask which endpoints the trial is measuring, how central-laboratory results will be shared with you, and how the study protocol defines success before you decide whether to take part[6].
Summary
Phase II trials sit at the point in medicine development where a treatment is first tested for whether it actually helps the patients it is designed for. This testing happens in groups of roughly 100 to 500 people, over a period usually measured in weeks to months, and it follows on directly from the safety and dosage groundwork laid in phase I[1]. This is also where dosing is refined, where randomisation and blinding are used to reduce bias, and where a large share of experimental medicines are found not to work well enough or to carry unexpected risks — which is why only a fraction of phase II treatments ever reach phase III[2].
As a patient or caregiver, the value of understanding this phase is practical: it tells you what questions to ask, what "proof of concept" really means, and why a promising phase II result is encouraging news rather than a guarantee[3]. Informed consent, strict inclusion criteria and Good Clinical Practice rules exist specifically to protect you throughout this process[7].
❓ How many patients usually take part in a phase 2 clinical trial?
Phase II trials are usually performed on groups of around 100 to 500 patients who have the disease or condition being studied, often with more than 30 participants per treatment group. The FDA describes phase 2 as involving up to several hundred people with the disease or condition.
❓ How long does a phase 2 trial last?
Phase II trials are typically short, lasting several weeks to a few months according to EUPATI's Open Classroom. The FDA gives a broader range, stating that phase 2 studies can last from several months up to two years.
❓ What is the difference between phase 1 and phase 2 trials?
Phase 1 trials mainly test safety and dosage, typically in 20 to 100 healthy volunteers or patients, and are often the first time a drug is given to humans. Phase 2 trials test the same drug in patients who have the disease it is meant to treat, focusing on whether it works (efficacy) while continuing to monitor safety and side effects.
❓ What does "proof of concept" mean in a phase 2 trial?
Proof of concept means researchers have found some clear sign of clinical improvement or activity in patients who received the treatment, often measured using surrogate endpoints rather than final clinical outcomes. It is not the same as confirmed efficacy, which is established later in phase III.
❓ Will I know if I am receiving the active medicine or a placebo?
In many phase II trials, no. These studies are often run as double-blind, randomised, placebo-controlled studies, meaning neither you nor your doctor knows whether you are receiving the active medicine, the current best treatment, or a placebo, until the trial data is unblinded.
❓ What percentage of drugs move from phase 2 to phase 3?
According to the FDA, approximately 33% of drugs that enter phase 2 trials move on to phase 3. By comparison, approximately 70% of drugs that enter phase 1 progress to phase 2, and roughly 25–30% of drugs in phase 3 move on to phase 4 or approval.
❓ Why can a treatment that worked in phase 2 fail in phase 3?
Phase 2 trials are relatively small and are not designed to provide definitive evidence of efficacy or safety on their own. Published literature documents cases where promising phase 2 results in efficacy or safety were not confirmed once the treatment was tested in a larger, randomised phase 3 trial.
- [1] Phase II - Typically Therapeutic Exploratory: Introduction (accessed 2 June 2026) — https://learning.eupati.eu/mod/book/view.php?id=360
- [2] Step 3: Clinical Research (accessed 2 June 2026) — https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
- [3] Phase II Trials (accessed 2 June 2026) — https://toolbox.eupati.eu/resources/phase-ii-trials/
- [4] Clinical trials in cancer — Knowledge Hub (accessed 2 June 2026) — https://www.genomicseducation.hee.nhs.uk/genotes/knowledge-hub/clinical-trials-in-cancer/
- [5] https://pmc.ncbi.nlm.nih.gov/articles/PMC8688307/
- [6] Making a medicine. Step 7: Phase II - Proof of concept (accessed 2 June 2026) — https://toolbox.eupati.eu/resources/making-a-medicine-step-7-phase-ii-proof-of-concept/
- [7] Clinical Trials - Paul-Ehrlich-Institut (accessed 2 June 2026) — https://www.pei.de/EN/regulation/clinical-trials/clinical-trials-content.html
- [8] A Phase 2 open-label basket study to evaluate the efficacy and safety of orally administered reversible tyrosine kinase inhibitor BAY 2927088 (accessed 2 June 2026) — https://my.clevelandclinic.org/clinical-trials/2230-a-phase-2-open-label-basket-study-to-evaluate-the-efficacy-and-safety-of-orally-administered-reversible-tyrosine-kinase-inhibitor-bay-2927088-in-participants-with-metastatic-or-unresectable-solid-tumors-with-her2-activating-mutations
